We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JTAI:NASDAQJet.AI Inc. Analysis

Data as of 2026-06-21 - not real-time

$7.03

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Jet.AI Inc. (JTAI) trades around $7, just above its 30‑day support of $5.82 and well below the $9.5 resistance, with the 20‑day SMA (7.68) modestly above the 50‑day SMA (7.25) indicating a neutral short‑term trend. The RSI sits at 45, suggesting neither overbought nor oversold conditions, while the MACD histogram is negative and the signal line is bearish, pointing to modest downside momentum. Volatility is extreme at over 108% 30‑day, beta exceeds 1.6, and the historic max drawdown approaches 100%, underscoring a highly speculative price profile.
Fundamentally, the company reports a 51% revenue decline, negative gross and operating margins, and a massive EBITDA loss of $9.8 M, with operating and free cash flow deeply negative. Valuation metrics are strikingly low – a trailing P/E of 0.02 versus an industry average of 38, a price‑to‑book of 0.13 and a price‑to‑sales of 1.35, while analysts’ consensus target price of $80 implies a >1,000% upside. Recent material news centers on a proposed merger with flyExclusive, with proxy advisors recommending a “FOR” vote, which could be a catalyst if executed, but the company’s cash burn and limited liquidity remain significant concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and decreasing volume signal limited upside
  • Price hovering near support with modest upside to resistance
  • Extreme volatility and high beta increase short‑term uncertainty

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Proposed merger with flyExclusive could unlock substantial value
  • Analyst target price suggests >1,000% upside
  • Current price reflects deep discount to book and sales metrics

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Sustained negative cash flow and EBITDA raise sustainability concerns
  • High volatility and beta imply continued price instability
  • Outcome of merger and post‑transaction integration remain uncertain

Key Metrics & Analysis

Financial Health

Revenue Growth-51.60%
Profit Margin68.77%
P/E Ratio0.0
ROE20.48%
ROA-21.09%
Debt/Equity1.01
P/B Ratio0.1
Op. Cash Flow$-9083503
Free Cash Flow$-5146724
Industry P/E38.1

Technical Analysis

TrendNeutral
RSI45.1
Support$5.82
Resistance$9.50
MA 20$7.68
MA 50$7.25
MA 200$211.46
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46

Valuation

Target Price$80.00
Upside/Downside1037.98%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.61
Volatility108.29%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.